

1 **Availability, market share and price of quality assured**
2 **artemisinin-based combination therapies in private drug**
3 **outlets after over a decade of Copayment mechanism in**
4 **Uganda.**

5 Moses Ocan^{1*}, Winnie Nambatya², Caroline Otike³, Loyce Nakalembe⁴, Sam Nsobya⁵

6
7 *Author affiliations*

8 ¹Department of Pharmacology & Therapeutics, College of Health Sciences, Makerere University, P. O.
9 Box 7072, Kampala.

10 ²Department of Clinical Pharmacy, College of Health Sciences, Makerere University, P. O. Box 7072,
11 Kampala.

12 ³Data Department, Joint Clinical Research Centre, Lubowa, P. O Box 10005, Kampala, Uganda

13 ⁴Department of Pharmacology, Soroti University, P.O. Box 211, Soroti, Uganda

14 ⁵Department of Pathology, College of Health Sciences, Makerere University, P.O. Box 7072, Kampala,
15 Uganda

16

17 *Corresponding author: Moses Ocan, E-mail: ocanmoses@gmail.com; Tel: +256712234364

18

19

20

21

22

23

24

25

26

27

28

29

30 Abstract

31 **Background:** Malaria remains one of the leading causes of morbidity, and mortality in Uganda. A
32 large proportion of malaria symptomatic patients seek healthcare in the private sector. However,
33 availability and affordability are major barriers to access to effective treatment. The private sector
34 copayment mechanism in Uganda aims to increase availability and affordability of antimalarial agents.
35 Our study assessed the availability, price, and market share of quality assured artemisinin-based
36 combination therapies (QAACTs) in private drug outlets after over a decade of copayment mechanism in
37 the private sector in Uganda.

38 **Methods:** This was a cross-sectional survey of anti-malarial agents in private drug outlets in high
39 (Tororo, and Apac districts) and low (Kabale and Mbarara districts) malaria transmission settings.
40 Following the World Health Organization Health Action International (WHO/HAI) criteria, an audit of the
41 antimalarial agents was done using a checklist to determine availability, price, and market share of
42 QAACTs. Data was entered in Epi-data and analyzed in STATA ver 14.0 at 95% confidence level.

43 **Results:** A total of twenty-eight (28) private drug outlets (pharmacies and drug shops) were included
44 in the survey. One in seven Artemisinin-based combination therapies (ACTs) in the drug outlets were
45 quality assured (QAACTs). Artemether-lumefantrine (AL), 8.9% (11/124) and Artesunate-Amodiaquine
46 (AQ), 7.3% (9/124) were the only QAACTs present in the drug outlets at the time of the survey. The
47 majority, 86.1% (124/144) of antimalarial agents present in stock in the drug outlets were artemisinin
48 based. The most common, 38.9% (56/144) ACT in the drug outlets was Dihydroartemisinin-Piperaquine
49 (DHP). Most, 69.4% (100/144) of the antimalarial agents were in high malaria transmission settings. The
50 cost of ACT antimalarial agents is high in the country, USD 1.4 (Artemether-Lumefantrine, AL), USD 2.4
51 (Dihydroartemisinin-Piperaquine, DP), the first line and second-line agents respectively for treatment of
52 uncomplicated malaria in Uganda. There was a statistically significant difference between the dispensing
53 price of the 'Green leaf' ACTs and the recommended price ($p < 0.001$).

54 **Conclusion:** Quality assured artemisinin-based combination therapies (QAACTs) are not common
55 in private drug outlets in low and high malaria transmission settings. All the drug outlets had at least one
56 ACT antimalarial agent present on the day of the survey. The dispensing price of QAACTs was
57 significantly higher than the recommended markup price. There is need for awareness creation,
58 surveillance, and monitoring of the implementation of Copayment mechanism in the country.

59

60 *Key words: Quality assured artemisinin agents, non-artemisinin agents, malaria, cost, self-medication*

61

62

63

64

65

66 Introduction

67 The World Health Organization (WHO) reported an overall increase in malaria burden globally
68 of up to two million cases in 2020-2021 with most of the increase occurring in the WHO Africa
69 region (1). Uganda is among the four countries including Nigeria, Democratic Republic of Congo
70 and Mozambique that accounted for nearly half of all malaria cases globally in 2020-2021 (1).
71 Malaria thus remains a disease of public health concern in Uganda accounting for 30-50% of all
72 out-patient visits, and 15-20% of all hospital admissions (2). The healthcare system in Uganda
73 like most other low-and middle-income countries (LMICs) is faced with multiple challenges
74 including inadequate human resource and limited funding (3). The unreliable supply coupled
75 with high costs of antimalarial agents in health facilities common in most LMICs potentially
76 affect malaria treatment (4, 5). In Uganda, this is likely to be worsened by the high burden of
77 malaria.

78 In most low-and middle-income countries (LMICs), over 60% of the population first seek
79 treatment in the private sector (6). A study by Ocan *et al.*, (7) reported over half of population
80 in northern Uganda accessing antimalarial agents over the counter in private drug outlets. The
81 sector thus plays an integral role in the fight against malaria (8). Patients seeking malaria
82 treatment in the private sector are however faced with multiple challenges including high cost,
83 unreliable supply, and substandard antimalarial agents (5, 9). In most malaria affected countries
84 price remains the leading contributor to limited access to antimalarial agents (5, 10). These
85 potentially affects access to appropriate malaria treatment which potentially predisposes
86 patients to adverse treatment outcomes including exacerbation of the current resistance to
87 first-line antimalarial agents.

88 One of the key factors influencing access to appropriate malaria treatment is pricing of
89 antimalarial agents (5). The Affordable medicines facility for malaria (AMFm) is a financing
90 mechanism incorporating three elements; price reductions through negotiations with
91 manufacturers of quality-assured ACTs (QAACTs), a buyer subsidy to the participating
92 manufacturers, and interventions to support AMFm implementation and promote appropriate
93 antimalarial use (11). Affordable Medicines Facility-malaria (AMFm), funded by three donors
94 (UNITAID, the UK government and the Bill & Melinda Gates Foundation) was renamed as the

95 private sector co-payment mechanism and integrated into the existing Global Fund grants (12).
96 The AMFm initiative is intended to improve availability, affordability, and access to quality
97 assured artemisinin-based combination therapies (QAACTs) in the private sector (13). Under
98 the AMFm, public and private importers pay manufacturers a subsidized price between \$0.005
99 and \$ 0.22 per treatment course, representing 1-20% of the manufacturer price (14). The
100 balance is then paid to the manufacturer via the co-payment fund (14). Uganda was part of the
101 countries where the initiative was first piloted and subsequently implemented the Copayment
102 mechanism following the AMFm transition period in 2013 (13).

103 Negotiations with manufacturers under the AMFm led to reductions in manufacturer price for
104 sales to private-for-profit buyers of up to 29-78% depending on package size, bringing prices
105 down to around the levels paid by public purchasers (15). This helped improve availability,
106 affordability, and access to QAACTs in the AMFm pilot countries. In Uganda the AMFm was
107 replaced by Copayment mechanism following the end of the pilot period (13). The approved
108 quality assured ACTs in Uganda include Artemether/lumefantrine, Artesunate/Amodiaquine,
109 Dihydroartemisinin/piperaquine, and Artesunate/Pyronaridine (16, 17). Uganda is currently
110 implementing 70% subsidy for all package sizes of QAACTs (13). However, the impact of the
111 Copayment mechanism in the private sector remains unclear. Therefore, this study assessed
112 availability, price, and market share of quality assured artemisinin-based combination therapies
113 (QAACT) in the private drug outlets in low and high malaria transmission settings in Uganda
114 after over a decade of implementing Copayment mechanism.

115 **Methods**

116 **Study design and setting**

117 This was a cross-sectional study conducted in low (Kabale and Mbarara districts) and high (Apac
118 and Tororo districts) malaria transmission settings. Data on antimalarial agents present in the
119 drug outlets on the day of the survey was collected.

120

121 **Sample size, drug outlet selection and sampling**

122 In each district (Tororo, Apac, Mbarara and Kabale), a comprehensive list of the available
123 private drug outlets was compiled using the National drug authority register of drug outlets.
124 Additionally, a census was taken to identify all the private drug outlets (pharmacies and drug
125 shops) in each district prior to data collection. All the drug outlets identified from the National
126 drug authority register and the census were then included in the survey. Private drug outlets in
127 this study are defined as for-profit licensed establishments that dispense medicines. Two
128 research assistants, a pharmacist (KJ) and nurse (RK) conducted the antimalarial drug audit in
129 the private drug outlets. Each of the research assistants separately visited different drug outlets
130 in the study districts. At each drug outlet prior to data collection the research assistants
131 introduced themselves and explained the study and provided approval letters from the Ethics
132 committee, UNCST and local authorities. The research assistants obtained a written informed
133 consent from the pharmacists/dispensers in each pharmacy prior to data collection which was
134 done between 15th June 2021- 21st December 2021. In each study district, the research
135 assistants moved from one drug outlet to the next until all the identified private drug outlets
136 were covered.

137

138 **Data collection**

139 The WHO/HAI methodology was used for collection of data on availability and price of
140 antimalarial agents. In each drug outlet, the dispenser/pharmacist was requested to show the
141 research assistants all the antimalarial agents available in stock on the day of the survey.
142 Additionally, a stock card and dispensing logs were also obtained and screened. An audit of the
143 antimalarial agents that were provided, stock cards and dispensing logs was then done using a
144 data collection checklist. The tool was pre-tested in drug outlets in Kampala city and validated.
145 Data was collected for each identified anti-malarial agent in the drug outlet. The WHO list of
146 antimalarial agents was used in identification of antimalarial agents present in stock during the
147 day of the survey. Additionally, the Ministry of Health list of quality assured artemisinin-based
148 agents in the country was also used in identifying QAACTs in the drug outlets. Data was
149 collected on, drug outlet type, generic name, brand name, active ingredients and strengths,

150 formulation, quality assured ACT (having a green leaf logo), non-quality assured ACT (without a
151 green leaf logo), manufacturer and country of manufacture, type of antimalarial (artemisinin or
152 non-artemisinin based), location of drug outlet (transmission setting), and package size. The
153 price of the antimalarial agents was collected from the dispensing logs and the
154 dispenser/pharmacist.

155 During each data collection day, the lead researcher reviewed all the data collection forms and
156 visited 20% of all the drug outlets for quality control checks. Any discrepancies in the data
157 collection tool were rectified through discussion with the data collectors and consensus.

158 **Data management and analysis**

159 In this study, ACT antimalarial agents were classified into two categories: i) quality assured ACTs
160 (QAACTs) are ACTs that comply with the Global Fund's ACT chemical regulation and have a
161 green leaf logo printed on its label and ii) non-quality assured ACTs (non-QAACTs) which are
162 ACTs without the green leaf logo on their labels. The Quality-assured ACTs were further divided
163 into two categories: i) quality-assured first-line ACT (Artemether/Lumefantrine) and ii) quality-
164 assured alternative first-line ACT (Artesunate/Amodiaquine) as per the national malaria
165 treatment guidelines (18). Antimalarial availability was measured as the proportion of outlets
166 with at least one anti-malarial agent present on the day of data collection (survey). Additionally,
167 in each private drug outlet the proportion of specific anti-malarial categories present in stock
168 during the day of the survey was also calculated. The prices of antimalarial agents in the drug
169 outlets were converted to US dollars using the average annual exchange rate by the Bank of
170 Uganda in 2021. The antimalarial price data at the time of data collection is reported in terms
171 of adult equivalent doses, defined as the amount needed to treat a 60 kg adult (19).

172 Data was entered in EpiData *version* 4.2.0.0 and exported to STATA *version* 14.0 for cleaning
173 and analysis. Antimalarial agents were summarized using frequencies and proportions,
174 prevalence of antimalarial agents was also determined using proportions. Distribution of
175 antimalarial agents across malaria transmission settings and type of drug outlet was compared
176 using fisher's exact test of independence at 95% level of significance. Price of antimalarial
177 agents was summarized using median and interquartile range.

178 **Results**

179 **Descriptive results**

180 A total of twenty-eight (28) drug outlets were included in the survey of which majority, 78.6% (22/28)
181 were pharmacies. All the drug outlets in the study districts (Apac, Tororo, Mbarara and Kabale) had at
182 least one antimalarial agent present in stock during the day of the survey. Of the 28 drug outlets visited
183 in this study, majority 82.1% (23/28) had a minimum of 5 different kinds of antimalarial agents present
184 on the day of the survey. Most, 69.4% (100/144) of the antimalarial agents were in high malaria
185 transmission settings. The majority, 86% (124/144) of the antimalarial agents were tablet formulations.
186 Twelve, 8.3% (12/144) of the artemisinin based antimalarial agents in the drug outlets were
187 monotherapies (Table 1).

188

189 **Antimalarial agents present in the drug outlets on the day of the** 190 **survey.**

191 A total of 144 antimalarial agents were present in the drug outlets on the day of the survey of which
192 majority, 86.1% (124/144) were artemisinin-based agents. Of the Artemisinin based combination
193 therapies, 61.1% (88/144) were in high malaria transmission settings and 68.8% (99/144) were found in
194 pharmacies. For non-artemisinin based antimalarial agents, 8.3% (12/144) were in high malaria
195 transmission setting and 11.1% (16/144) were in pharmacies.

196 Of the artemisinin-based agents, majority 90.3% (112/124) were Artemisinin-based combination
197 therapies (ACTs). Artesunate was the most common artemisinin monotherapy, 8.9% (11/124). All the
198 artemisinin monotherapies 9.7% (12/124) were injectables (Artemether and Artesunate). Over a third
199 35.4% (51/144) of the antimalarial agents were first-line ACTs (Artemether-lumefantrine, 29.2%: 42/144
200 and Artesunate-amodiaquine, 6.3%: 9/144). Most first-line ACTs, 26.4% (38/144), 25.7% (37/144) were
201 in high malaria transmission setting and pharmacies respectively. Of the ACTs 70.2% (87/124), 66.9%
202 (83/124) were present in pharmacies and high malaria transmission settings respectively. There was no
203 statistically significant difference in the presence of ACTs in pharmacies and drug shops ($p=0.318$).
204 However, there was a statistically significant difference in the distribution of ACTs based on setting
205 ($p=0.03$).

206 Four batches, 2.8% of the Artemisinin based antimalarial agents available in stock in the drug outlets
207 had passed their expiry date. Of the expired agents, three were artemisinin-based while one was a non-
208 artemisinin-based agent (Table 1).

209

210 **Availability of Quality Assured Artemisinin Combination therapies** 211 **(QAACTs)**

212 One in every seven Artemisinin-based combination therapies in the drug outlets were Quality Assured
213 Artemisinin combination agents ('Green leaf ACTs'; QAACT). Most, 9.7% (12/124) of the QAACTs were in
214 pharmacies. The QAACTs were common, 13.7% (17/124) in drug outlets in high malaria transmission
215 settings. The QAACTs were significantly distributed in the pharmacies within the study settings
216 ($p=0.031$). While there was no significant difference in the distribution of QAACTs by malaria
217 transmission setting ($p=0.123$). Artemether-lumefantrine (AL), 8.9% (11/124) and Artesunate-
218 Amodiaquine (AQ), 7.3% (9/124) were the only QAACTs present in drug outlets on the day of the survey.
219 All the Artesunate/Amodiaquine agents in drug outlets were 'Green leaf' ACTs (Table 1).

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245 **Table 1: Antimalarial agents (N=144) in drug outlets in high and low malaria transmission settings in**
 246 **Uganda**

Antimalarial category	Description	Overall n (%)	Low malaria transmission n (%)	High malaria transmission n (%)	p-value
Artemisinin monotherapies	Artesunate	11 (7.6)	6 (4.1)	5 (3.5)	1.00
	Artemether	1 (0.7)	1 (0.7)	0	
Non-Artemisinin based monotherapies	Chloroquine	2 (1.4)	1 (0.7)	1 (0.7)	1.00
	Quinine	8 (5.6)	3 (2.1)	5 (3.5)	
	Mefloquine	1 (0.7)	0	1 (0.7)	
Artemisinin-based combination therapies (ACTs)	Artemether/lumefantrine	42 (29.1)	13 (9)	29 (20.1)	0.213
	Artesunate/Amodiaquine	9 (6.3)	0	9 (6.3)	
	Dihydroartemisinin/Piperaquine	56 (38.9)	15 (10.4)	41 (28.5)	
	Artesunate /Mefloquine	2 (1.4)	1 (0.7)	1 (0.7)	
	Artesunate/Pyronaridine	3 (2.1)	0	3 (2.1)	
Non-Artemisinin based combination therapies	Atovaquone/Proguanil	2 (1.4)	1 (0.7)	1 (0.7)	1.00
	Sulfadoxine/Pyrimethamine	7 (4.9)	3 (2.1)	4 (2.8)	
Quality Assured ACTs ('Green leaf ACTs)	Artemether/lumefantrine	11 (7.6)	3 (2.1)	8 (5.5)	0.218
	Artesunate/Amodiaquine	9 (6.3)	0	9 (6.3)	
Expired antimalarial agents	Yes	4 (2.8)	1 (0.7)	3 (2.1)	1.00
	No	140 (97.2)	43 (29.9)	97 (67.3)	
Formulation	Powder	18 (12.5)	10 (6.9)	8 (5.5)	0.039
	Syrup	2 (1.4)	0	2 (1.4)	
	Tablets	124 (86.1)	34 (23.6)	90 (62.5)	

247 *ACTs: Artemisinin-based Combination therapies; n=sample size; %: percentage*

248

249

250

251

252

253 **Price of antimalarial agents in drug outlets in Uganda**

254

255 Arterolane maleate/piperaquine phosphate combination had highest median price among the
256 antimalarial combination agents, 4.9 USD. The median price for Artemether/lumefantrine (AL),
257 the first line agent for uncomplicated malaria in Uganda was 1.4 USD.
258 Dihydroartemisinin/Piperaquine (DP), the second-line agent for treatment of uncompleate
259 malaria in Uganda cost was sold at a median price of 1.7USD. Artesunate + Amodiaquine
260 (AS+AQ), the second-line alternative agent for uncompleate treatment of uncompleate malaria
261 in Uganda the median price was 2.1 USD (Table 2).

262

263 **Table 2: Median price of oral antimalarial agents in drug outlets in Uganda**

S/N	Generic name	Median price (USD)	IQR (USD)
1.	Artemether/Lumefantrine	1.4	0.9, 1.9
2.	Arterolane maleate/piperaquine Phosphate	4.9	2.4, 5.6
3.	Artesunate + Amodiaquine	0.8	0.7, 1.3
4.	Artesunate/Mefloquine	2.8	2, 4.2
5.	Chloroquine Phosphate	0.6	0.5, 0.8
6.	Dihydroartemisinin/Piperaquine	3.2	2.7, 4.2
7.	Mefloquine	1.1	0.7, 2.2
8.	Quinine sulphate	0.4	0.3, 0.4
9.	Sulfadoxine/Pyrimethamine	0.6	0.1, 0.4
10.	Atovaquone/Proguanil	1.9	1.8, 2.0
11.	Artesunate/Pyronaridine	2.2	0.1, 2.8
12.	Arterolane maleate/piperaquine Phosphate	4.9	2.4, 5.6

264 *USD: US dollar, IQR: Interquartile range*

265

266

267

268

269

270

271

272 **Price mark-ups on quality assured artemisinin-based combination** 273 **therapies (QAACTs) in drug outlets in Uganda**

274 The median dispensing price for adult dose of quality assured (QAACT: 'Green leaf') first-line
275 ACT for uncomplicated malaria, artemether-lumefantrine (AL) (20/120mg) was USD 0.98, which
276 is higher than the recommended retail price by 10.2%. The median dispensing price for quality
277 assured Artesunate/Amodiaquine (AQ) (25/67.5mg) was USD 0.7 which is higher than the
278 recommended retail price by 57%. There was a statistically significant difference between the
279 dispensing price of the 'Green leaf' ACTs and the recommended retail price ($p < 0.001$).

280

281 **Discussion**

282 The study found at least one antimalarial agent present in all drug outlets during the day of the
283 survey. Additionally, Artemisinin-based combination therapies (ACTs) were the most common
284 antimalarial agents in the drug outlets. This is unlike the findings of a previous study by
285 O'Connell et al., (20) done in six sub-Saharan African countries that reported a low prevalence
286 of ACTs in private sector. The implementation of Affordable medicines facility for malaria
287 (AMFm) program could have influenced the difference in the findings of the two studies. A
288 study by ACTwatch group *et al.*, (13), reported an increase on availability of ACTs following
289 implementation of the AMFm-malaria program. The finding of our study is an indicator of wide
290 availability of Artemisinin-based combination therapies (ACTs), the current cornerstone for
291 malaria treatment in private drug outlets.

292 The immediate post AMFm pilot period was characterized by increases in the availability of
293 QAACTs in the private sector in Uganda and all other countries where it was implemented (13,
294 14). However, our study found a low prevalence of QAACTs in private drug outlets after over a
295 decade of implementing copayment mechanism following AMFm pilot period. This is like
296 findings of a study by O'Connell et al., (20). The low availability of QAACTs in private drug
297 outlets highlights the challenges of implementation of copayment mechanism especially lack of

298 supporting interventions like training of private sector healthcare personnel and behavioral
299 change communication (13, 14).

300

301 The study did not find oral artemisinin-based monotherapies in the drug outlets. The injectable
302 artemisinin monotherapies (Artesunate and Artemether) were however common. According to
303 the National malaria case management guidelines, injectable artemisinin agents are indicated
304 in the treatment of severe malaria and are to be used alongside oral ACTs. The use of oral
305 artemisinin monotherapies in malaria treatment was reported in Southeast Asia as one of the
306 drivers of artemisinin resistance development (21). Our findings are like those of a previous
307 study by ACTwatch et al., (13) and O'Connell et al., (20) who reported not finding artemisinin-
308 based monotherapies in sub-Saharan Africa. The objectives of the AMFm were to make the
309 ACTs more available, accessible and to crowd out artemisinin monotherapies (13). The findings
310 of our study could thus be due to the emphasis placed on the Artemisinin based combination
311 therapies through the AMFm and Copayment mechanism in the country. In addition, the
312 absence of artemisinin monotherapies in Uganda could be due to the World Health
313 Organization (WHO) recommendation to malaria affected countries to ban importation and
314 manufacture of these agents.

315 The study found non-artemisinin antimalarial agents in the drug outlets across the country. This
316 is like the findings of a study by O'Connell et al., (20) which reported high prevalence of non-
317 artemisinin agents in sub-Saharan African countries. Our study found, chloroquine, quinine and
318 Sulphadoxine/Pyrimethamine (SP) as common non-artemisinin agents in drug outlets. Presence
319 of non-artemisinin therapies in the private drug outlets could be due to their perceived
320 effectiveness and familiarity from previous use coupled with provider behavior and beliefs (7,
321 22). Sulphadoxine/Pyrimethamine (SP) is recommended for use in prophylaxis against malaria
322 in pregnancy (23). Additionally, Quinine is a second line agent in treatment of severe malaria in
323 the country (18). However, the use of chloroquine was discontinued in 2006 (24) due to
324 widespread resistance. The continued presence of chloroquine in private drug outlets is an
325 indicator of access and use by communities in management of symptoms of malaria. Recent

326 studies in Uganda have reported persistence of *P. falciparum* resistance against chloroquine
327 over two decades after discontinuation of its use in the country (25). Therefore, continued use
328 of chloroquine by communities is likely to lead to inadequate treatment and increased risk of
329 unwanted malaria treatment outcomes.

330 Dihydroartemisinin/Piperaquine (DP) and Artemether/lumefantrine (AL), the two most popular
331 ACTs had a high median dispensing price for a full adult dose ranging from USD 1.4 – 2.4. The
332 median price of the subsidized ACTs ('Green leaf ACTs') was also significantly higher than the
333 non-subsidized agents. This is similar to the prices reported in a study by O'Connell et al., (20)
334 done in six malaria endemic countries in sub-Saharan Africa. A previous study by Tougher et al.,
335 (14) also found no significant change in ACT prices following implementation of AMFm pilot
336 program in Uganda. In a country where majority of the rural communities live under USD 1.0 a
337 day, the reported prices of ACTs are potentially prohibitive. The reported high cost of ACTs
338 potentially hinders access to appropriate and effective malaria treatment in the country.
339 Recent studies in Uganda have reported high over-the-counter access of antimalarial agents
340 which coupled with the high cost of ACTs could drive inappropriate use (7, 26). With the
341 emerging artemisinin resistance, inappropriate use of ACTs is likely to exacerbate malaria
342 parasite resistance in the country (27). The high cost of quality assured ACTs in the private
343 sector despite government subsidy highlights the challenge of implementation of government
344 programs especially in LMICs. There is thus need for regular monitoring of the implementation
345 of copayment mechanism for improvement of availability and access to quality assured ACTs in
346 the private sector.

347 The study had some limitations, the overt method used is likely to be affected by the
348 pharmacists not reporting the actual practice in the pharmacy. However, the additional review
349 of stock cards and drug dispensing logs in the pharmacies and drug shops helped collaborate
350 the findings of the study.

351

352

353 **Conclusion:**

354 The results of our study indicate low prevalence of QAACTs in private drug outlets after over a
355 decade of implementation of copayment mechanism in Uganda. Prices of both QAACTs and
356 non-QAACTs remain high in private drug outlets (pharmacies and drug shops) despite the
357 subsidies on QAACTs. There is need for consistent implementation of Copayment supporting
358 interventions to help create demand for QAACTs among private sector health providers and the
359 population. The Ministry of Health needs to conduct a review of the copayment mechanism to
360 establish barriers to its implementation in the country.

361 **Author contribution**

362 Conceptualization of the study (MO and SN), data curation and formal analysis (CO),
363 methodology and investigation (MO and LN), validation (WN), Writing-original draft preparation
364 (MO), supervision (SN). All the authors reviewed and edited the final version of the manuscript.

365 **Acknowledgements**

366 We acknowledge Mr. Tayebwa Mordecai and Ms. Joanita Birungi for managing and
367 coordinating field data collection. We are grateful to the research assistants, Ms. Ruth
368 Kokusiima, Ms. Kadesemba Phoenah, Mr. Olwortho Wilfred, and Mr. Kato Henry for the work
369 done during the field data collection. All authors read and approved the final manuscript.

370

371

372

373 **References**

- 374 1. World Health Organisation. World malaria report 2022. Geneva, Switzerland: WHO;
375 2022.
- 376 2. Ministry of Health. Malaria quarterly report. Kampala, Uganda: Ministry of Health; 2023.

- 377 3. Oleribe OO, Momoh J, Uzochukwu BS, Mbofana F, Adebisi A, Barbera T, et al. Identifying
378 Key Challenges Facing Healthcare Systems In Africa And Potential Solutions. *Int J Gen Med.*
379 2019;12:395-403.
- 380 4. Oridanigo EM, Salgado WB, Kebene FG. Affordability of essential medicines and
381 associated factors in public health facilities of Jimma Zone, Southwest Ethiopia. *Adv Pharmacol*
382 *Pharm Sci.* 2021;2021:1-9.
- 383 5. Palafox B, Patouillard E, Tougher S, Goodman C, Hanson K, Kleinschmidt I, et al. Prices
384 and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-
385 endemic countries. *Health Policy Plan.* 2016;31(2):148-60.
- 386 6. UBOS. Uganda national household survey 2016/17. Kampala, Uganda: Uganda Bureau of
387 Statistics 2017.
- 388 7. Ocan M, Bwanga F, Bbosa GS, Bagenda D, Waako P, Ogwal-Okeng J, et al. Patterns and
389 Predictors of Self-Medication in Northern Uganda. *PLoS One* 2014;9(3):e92323.
- 390 8. Davis B, Ladner J, Sams K, Tekinturhan E, de Korte D, Saba J. Artemisinin-based
391 combination therapy availability and use in the private sector of five AMFm phase 1 countries.
392 *Malar J.* 2013;12:135.
- 393 9. Ocan M, Nakalembe L, Otike C, Omali D, Buzibye A, Nsohya S. Pharmacopeial quality of
394 artemether-lumefantrine anti-malarial agents in Uganda. *Malar J.* 2023;22(1):165.
- 395 10. World Health Organisation. Medicines strategy 2008–2013. Geneva, Switzerland: WHO;
396 2008.
- 397 11. Adeyi O, Atun R. Universal access to malaria medicines: innovation in financing and
398 delivery. *Lancet.* 2010;376(9755):1869-71.
- 399 12. Opiyo N, Yamey G, Garner P. Subsidising artemisinin-based combination therapy in
400 the private retail sector. *Cochrane Database of Systematic Reviews.* 2016;3(3):CD009926.
- 401 13. ACTwatch Group, Tougher S, Hanson K, Goodman C. What happened to anti-malarial
402 markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price
403 and market share from five African countries under continuation of the private sector co-
404 payment mechanism. *Malar J.* 2017;16(1):173.
- 405 14. Tougher S, ACTwatch Group, Ye Y, Amuasi JH, Kourgueni IA, Thomson R, et al. Effect of
406 the Affordable Medicines Facility--malaria (AMFm) on the availability, price, and market share
407 of quality-assured artemisinin-based combination therapies in seven countries: a before-and-
408 after analysis of outlet survey data. *Lancet.* 2012;380(9857):1916-26.
- 409 15. Roll Back Malaria. Updated ACT prices under the Affordable Medicines Facility-malaria 1
410 March 2011 fact sheet. Geneva, Switzerland: WHO; 2011.
- 411 16. HEPS-Uganda. Assessing Access to Co-Paid Artemisinin-Based Combination Therapies for
412 Malaria in Uganda. Kampala, Uganda: Coalition For Health Promotion and Social Development
413 (HEPS-Uganda); 2017.
- 414 17. Ministry of Health. The Uganda Malaria Reduction Strategic Plan (2014–2020):
415 accelerated nationwide scale up to achieve universal coverage of cost effective malaria
416 prevention and treatment interventions. Kampala, Uganda: Ministry of Health (MoH); 2014.
- 417 18. Ministry of Health. Uganda National Malaria Control Policy. Kampala, Uganda: National
418 Malaria Control Program, Ministry of Health; 2011.

- 419 19. Shewchuk T, O'Connell KA, Goodman C, Hanson K, Chapman S, Chavasse D. The
420 ACTwatch project: methods to describe anti-malarial markets in seven countries. *Malar J.*
421 2011;10:325.
- 422 20. O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, et al. Got ACTs?
423 Availability, price, market share and provider knowledge of anti-malarial medicines in public
424 and private sector outlets in six malaria-endemic countries. *Malar J.* 2011;10:326.
- 425 21. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, et al. Artemisinin
426 resistance: current status and scenarios for containment. *Nat Rev Microbiol.* 2010;8(4):272-80.
- 427 22. Masanja IM, Lutambi AM, Khatib RA. Do health workers' preferences influence their
428 practices? Assessment of providers' attitude and personal use of new treatment
429 recommendations for management of uncomplicated malaria, Tanzania. *BMC Public Health.*
430 2012;12:956.
- 431 23. World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva,
432 Switzerland. : WHO; 2015.
- 433 24. Nanyunja M, Nabyonga Orem J, Kato F, Kaggwa M, Katureebe C, Saweka J. Malaria
434 treatment policy change and implementation: the case of Uganda. *Malar Res Treat.*
435 2011;2011:683167.
- 436 25. Asua V, Conrad MD, Aydemir O, Duvalsaint M, Legac J, Duarte E, et al. Changing
437 Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance
438 Across Uganda. *J Infect Dis.* 2021;223(6):985-94.
- 439 26. Sabot OJ, Mwita A, Cohen JM, Ipuge Y, Gordon M, Bishop D, et al. Piloting the global
440 subsidy: the impact of subsidized artemisinin-based combination therapies distributed through
441 private drug shops in rural Tanzania. *PLoS One.* 2009;4(9):e6857.
- 442 27. Yasri S, Wiwanitkit V. Artemisinin resistance: an important emerging clinical problem in
443 tropical medicine. *Int J Physiol Pathophysiol Pharmacol.* 2021;13(6):152-7.

444

445